Tracker / BPC-157
Is BPC-157 legal in the US?
Short answer · as of Oct 17, 2026
Not yet. BPC-157 isn't an FDA-approved drug, and it isn't on the 503A bulks list, the list that lets pharmacies compound a substance that has no approved version.
An FDA advisory committee voted 8–6 in July to recommend adding it, but that vote is advisory. On October 15, HHS and the FDA sent the White House an interim policy that could let pharmacies compound it while permanent rules are written. That policy hasn't been published and hasn't taken effect.
BPC-157 status, item by item
The legal question breaks into several smaller ones. Here's each, with today's answer.
| Question | Answer today | Status |
|---|---|---|
| Is it an FDA-approved drug? | No. There's no FDA-approved BPC-157 product, for any use. | No |
| Is it on the 503A bulks list? | No. This is the list that would let state-licensed pharmacies compound it for individual patients. | No |
| Is it still flagged as a “significant safety risk”? | No. It was among the twelve peptides the FDA took out of Category 2 in April 2026. That removed a barrier but didn't authorize compounding. | Flag lifted |
| Did the advisory committee recommend it? | Yes, 8–6 with one abstention, on July 23, 2026. FDA staff had recommended against it. | Recommended |
| Is there an interim policy allowing it? | One was sent to the White House for review on October 15. Its terms aren't public. | Pending |
| Is “research use only” BPC-157 legal to use? | No. Selling it for people to use makes it an unapproved drug, whatever the label says. | No |
What BPC-157 is
BPC-157 is a synthetic peptide modeled on a protein found in gastric juice. It's also known as Bepecin or PL-14736. “BPC-157” is a common name, not an official adopted drug name.
When the FDA evaluated it for the compounding list, it looked at BPC-157 for ulcerative colitis, taken by mouth, by injection under the skin, or by nasal, rectal, or skin application. Most of the research behind it is in animals. FDA reviewers found the human data limited and underpowered, and concluded that the evidence weighed against adding it to the list.
The FDA's search of its adverse event database, through December 3, 2025, turned up three cases. That low number isn't reassurance on its own. The FDA's briefing noted that pharmacies compounding under section 503A generally don't report adverse events to the agency, so problems may go unrecorded.
If BPC-157 isn't legal, why do clinics offer it?
Some clinics and pharmacies offer BPC-157 now. That doesn't mean it's authorized. A pharmacy compounding it today is taking on regulatory risk, and the FDA's April action lifted a safety flag without giving pharmacies permission to compound it.
If a provider offers you BPC-157, ask:
- Exactly what you'd be getting, and in what form.
- Which pharmacy makes it, and whether that pharmacy is licensed in your state.
- What legal basis the pharmacy is relying on to compound it today.
A provider who can't answer those clearly is telling you something. Our checklist for vetting a provider →
What would make BPC-157 legal to compound
There are two paths, and they're different things.
1. An interim access policy, possibly soon
The policy sent to the White House on October 15 would reportedly work through enforcement discretion. The FDA would signal that it won't take action against qualifying pharmacies that compound certain peptides, while permanent rules are worked out. BPC-157 would still be an unapproved drug. Which peptides it covers, and on what conditions, hasn't been made public.
2. A final rule adding it to the 503A list, likely later
Formal listing requires the FDA to propose a rule in the Federal Register, take public comment, and then issue a final rule. Law firms following the process say that commonly takes 8 to 12 months and can take longer.
Neither path makes BPC-157 an FDA-approved drug. Either one would mean a state-licensed pharmacy could prepare it for an individual patient with a prescription. State rules on prescribing and compounding would still apply.
Sources
- FDA briefing document: BPC-157 (July 2026 committee meeting)
- FDA: Pharmacy Compounding Advisory Committee meeting page
- FDA: Bulk drug substances used in compounding under section 503A
- AJMC: vote counts and FDA staff positions
- American Med Spa Association: the October 15 interim access policy
- Sheppard Mullin: what happened to the Category 2 peptides
Get an email when the FDA rules.
One short email when the FDA proposes or finalizes anything on peptide compounding, or when the GLP-1 rules change. Nothing else.